Clinical trial
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For…
NCT00375674 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00375674 |
|---|---|
| Title | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer |
| Official title | Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc |
| Acronym | S-TRAC |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Neoplasms |
| Intervention type | Drug, Other |
| Interventions | Sunitinib malate, Placebo |
| Enrollment | 674 |
| Start date | Aug 1, 2007 |
| Primary completion | Apr 7, 2016 |
| Completion | Sep 7, 2017 |
| First posted | Sep 13, 2006 |
| Last update posted | Sep 21, 2018 |
| Countries | Australia, China, Colombia, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Malaysia and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: